Eli Lilly's stock drops as it slashes the price of Zepbound: Time to buy the dip?

Eli Lilly's decision to reduce the price of its popular weight loss drug makes more sense than it appears at first. The ...

A better Ozempic? Eli Lilly’s new obesity drug cut weight by 23%, study finds

In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Fierce Biotech

Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some

Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...

Eli Lilly cuts Zepbound price to widen access for obesity drug

Eli Lilly said it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...